Study Highlights**WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?**☑ With the increasing application of next generation sequencing (NGS) to known "pharmacogenes," large numbers of open reading frame (ORF) "variants of unknown significance" (VUS) are being identified. However, the functional implications of those VUS remains unclear. **WHAT QUESTION DID THIS STUDY ADDRESS?**☑ This study was designed to determine whether the application of DMS might make it possible to determine the functional effects of VUS that have been observed in the ORFs of cytochrome P450 family 2 subfamily C member 9 (*CYP2C9*) and cytochrome P4540 family 2 subfamily C member 19 (*CYP2C19*). **WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?**☑ The results of the study demonstrate that deep mutational scanning (DMS) can be used to determine the functional implications of ORF VUS in *CYP2C9* and *CYP2C19*. **HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?**☑ The application of DMS to additional pharmacogenes would potentially expand the accuracy and clinical utility of the application of NGS to pharmacogenomics.

Genetic polymorphisms in or near pharmacogenes are a major cause of individual variation in drug response phenotypes.[1](#cts12758-bib-0001){ref-type="ref"} Cytochrome P450 family 2 subfamily C member 9 (*CYP2C9*) and cytochrome P450 family 2 subfamily C member 19 (*CYP2C19*) are genes that encode important cytochrome P450 enzymes that catalyze the phase I biotransformation of a variety of therapeutic drugs, including antiplatelet agents, selective serotonin reuptake inhibitors, and proton pump inhibitors.[2](#cts12758-bib-0002){ref-type="ref"}, [3](#cts12758-bib-0003){ref-type="ref"}, [4](#cts12758-bib-0004){ref-type="ref"}, [5](#cts12758-bib-0005){ref-type="ref"} Several years ago, the Mayo Clinic launched the RIGHT 1K study, in which next generation DNA sequencing (NGS) was performed with DNA from 1013 Mayo Biobank participants to identify variants in 84 pharmacogenes, including *CYP2C9* and *CYP2C19*.[1](#cts12758-bib-0001){ref-type="ref"}, [6](#cts12758-bib-0006){ref-type="ref"} However, many of the polymorphisms observed in those patients were variants of unknown significance (VUS).[1](#cts12758-bib-0001){ref-type="ref"}, [7](#cts12758-bib-0007){ref-type="ref"}, [8](#cts12758-bib-0008){ref-type="ref"} In a recent publication, we functionally characterized six novel nonsynonymous open reading frame (ORF) variants in the *CYP2C9* gene and seven nonsynonymous ORF variants in the *CYP2C19* gene observed in DNA from participants in the Right 1K study.[9](#cts12758-bib-0009){ref-type="ref"} Conventional methods for the characterization of individual sequence variants "one‐at‐a‐time" are reliable, but they are also time‐consuming, labor‐intense, and not easily scalable. As a result, only a limited number of variants can practically be investigated in that fashion. To help address this challenge, predictive algorithms, such as Polyphen‐2, SIFT, and PROVEAN, among others, represent efforts to help identify deleterious variants, but their reliability is variable and inadequate for clinical application.[10](#cts12758-bib-0010){ref-type="ref"}, [11](#cts12758-bib-0011){ref-type="ref"}, [12](#cts12758-bib-0012){ref-type="ref"} Laboratory‐based assays are still required to reliably interpret the impact of ORF missense variants on protein function. As a result, a significant gap remains in the functional interpretation of the large number of missense VUS being discovered as DNA sequencing is applied ever more broadly. Deep mutational scanning (DMS) methods provide a platform with which a large number of missense variants can be interrogated in parallel.[13](#cts12758-bib-0013){ref-type="ref"}, [14](#cts12758-bib-0014){ref-type="ref"} For example, Fowler *et al*. developed a DMS assay for all possible variants in clinically important genes, such as *BRCA1*,*TPMT*, and *PTEN*, linking genotypes to functionally determined phenotypes.[15](#cts12758-bib-0015){ref-type="ref"}, [16](#cts12758-bib-0016){ref-type="ref"} Specifically, engineered "landing pad" HEK 293T cells were used as a platform to integrate pooled variant libraries, resulting in one variant per cell for further functional assessment.[15](#cts12758-bib-0015){ref-type="ref"} DMS includes the creation of variant libraries for a gene, selecting the library for function (e.g., resistance to drug or fluorescence markers of protein quantity) and---finally---high‐throughput DNA sequencing of variants to link them with the "activity" assayed in a functional test.

In our previous "one‐at‐a‐time" functional genomic study, we identified a series of missense variants in the ORFs of *CYP2C9* and *CYP2C19* that resulted in decreased protein expression as a result of proteasome‐mediated degradation, presumably due to an alteration in protein folding. In the present study, fluorescence‐activated cell sorting (FACS) was used as a selection mechanism for cells expressing variant sequences (i.e., the cells were sorted according to the abundance of reporter protein expression). We should point out that saturation mutagenesis can also be used to create a "saturation" library, including all possible mutations for an ORF sequence in a single reaction, and that approach has been applied in some previous DMS studies.[15](#cts12758-bib-0015){ref-type="ref"} However, many of the variants created are unlikely to occur clinically. Therefore, we applied a different mutagenesis approach, nicking mutagenesis, to generate libraries that contained human genomic variation known to be present in the general population. Generation of variants by nicking mutagenesis is not exhaustive, but it is much more efficient than the generation of mutants one at a time by site‐directed mutagenesis.[17](#cts12758-bib-0017){ref-type="ref"}

In the present study, we have used DMS to analyze the functional implications of missense variants that have been observed in the ORFs of *CYP2C9* and *CYP2C19*, ORFs that were fused to green fluorescent protein (GFP). Recombinase was used to integrate the variant libraries into landing pad cells, one per cell. Multiplexed functional selection performed with FACS was then used to separate the cells into different "bins" based on fluorescence readout at the single cell level. Amplicon sequencing of DNA in each bin, followed by computational analysis of the frequency of variants appearing in each bin, was used to determine levels of protein expression. To identify potentially severely damaging variants for these two important *CYP* pharmacogenes, we analyzed 230 observed missense variants in ORFs present in a publicly available database consisting of exome sequencing  data for 60,000 general population subjects. We included genetic variants with allele frequencies (\> 0.00001) observed by the Exome Aggregation Consortium (ExAC; <http://exac.broadinstitute.org/>) as well as novel ORF VUSs from the Mayo Right 1K and Right 10K projects.[6](#cts12758-bib-0006){ref-type="ref"}, [9](#cts12758-bib-0009){ref-type="ref"}, [18](#cts12758-bib-0018){ref-type="ref"} The RIGHT 1K samples served as a control because we had already studied them individually.[9](#cts12758-bib-0009){ref-type="ref"} We found that 19 of 109 *CYP2C9* and 36 of the 121 *CYP2C19* missense variants that were studied displayed less than \~ 25% of the wild‐type (WT) protein expression, a level that might have clinical relevance.[9](#cts12758-bib-0009){ref-type="ref"} We also compared variant calling by the DMS method with the predictions of computational algorithms and, finally, we validated serverely damaging variants by the use of Western blot analysis. Our findings suggest that DMS can be an efficient method for the high‐throughput identification of low protein abundance ORF variants that might have potential clinical implications.

Methods {#cts12758-sec-0002}
=======

Generation of landing pad HEK 293T cells {#cts12758-sec-0003}
----------------------------------------

The landing pad construct and the promoter‐less cassette for CYP ORFs was created by Gibson assembly (**Supplemental Text**). TALENs were used to create double stranded breaks at the AAVS1 site and homology‐directed repair was used to introduce landing pad constructs into HEK 293T cells.[15](#cts12758-bib-0015){ref-type="ref"} The landing pad construct expressed doxycycline inducible blue fluorescent protein (BFP), which was used as a selection marker for landing pad insertion. Thirty percent of HEK 293T cells display hypotriploid karyotypes.[19](#cts12758-bib-0019){ref-type="ref"} The assay requires that a single variant be integrated per cell. Single cells were sorted into each well of a 96‐well plate for cloning. To identify which cells contained a single landing pad, we used Bxb1 recombinase mediated integration of a 1:1 ratio mixture of GFP and mCherry promotor‐less plasmids and analyzed fluorescence by flow cytometry. Clones having the lowest percentage of both GFP and mCherry were most likely to be candidate for further assay. The attB‐mCherry and attB‐GFP plasmids were transfected 24 hours after Bxb1 recombinase transfection, and BFP induction by doxycycline. After 5 days, candidate clones were trypsinized, washed with phosphate‐buffered saline, and were fixed in 4% formaldehyde at 4°C for 10 minutes. The cells were analyzed by flow cytometer FACS CantoX (BD Biosciences, San Jose, CA) and by the use of FACSDiva version 8.0 software and Flowjo software version 10 (BD Biosciences). The FACS CantoX instrument utilizes colinear 405, 488, and 561 nm lasers plus forward and side angle light scatter. Fluorescence images of variants were visualized using fluorescence microscopy (EVOS FLoid Cell Imaging Station; Life Technologies, Waltham, MA).

Nicking mutagenesis for variant library preparation {#cts12758-sec-0004}
---------------------------------------------------

Nicking mutagenesis methods were modified from Whitehead *et al*. to construct variant libraries for ORFs containing *CYP2C9* and *CYP2C19* missense variants.[17](#cts12758-bib-0017){ref-type="ref"} Nicking mutagenesis uses Nt.BbvCI and Nb.BbvCI sites and exonuclease cleavage to degrade WT template DNA. Nt.BbvCI enzyme with nicking endonuclease and exonuclease digestion of WT template DNA was used to form single stranded DNA. At the annealing step, five oligos carrying the variant of interest were annealed separately to single strand templates and then pooled with five reactions in one pot, using high fidelity DNA polymerase and Taq ligase to close the double strand. The second template strand was degraded by Nb.BbvCI endonuclease cleavage and exonuclease digestion, and a new second strand was synthesized with a common primer on a cassette plasmid backbone. Phosphorylated oligos for *CYP2C9* and *CYP2C19* variants were purchased from IDT (Coralville, IA). Sanger sequencing was used to validate the sequences of variant clones. Detailed protocols are provided in the **Supplemental Text**.

Fluorescence‐activated cell sorting {#cts12758-sec-0005}
-----------------------------------

Library cells were washed, trypsinized, and resuspended in phosphate‐buffered saline containing 5% fetal bovine serum. Cells were then sorted on an FACSAria with 407, 488, and 532 nm lasers (BD Biosciences) into four bins, and the cells were collected in culture medium. BFP^−^/mCherry^+^ cells containing *CYP2C9* or *CYP2C19* variants were flow sorted and grown for 5 days. BFP^‐^/mCherry^+^ cells were sorted again to determine the protein expression of *CYP2C9*/*CYP2C19* variants based on their GFP/mCherry ratios. Gates were set based on GFP/mCherry ratios for cells integrating known *CYP2C9*/*CYP2C19* variants and WT proteins as gating references. Four gates were set to dissect the pooled libraries into four different bins based on GFP/mCherry ratios. Data were analyzed by FACSDiva version 8.0.1 software.

Variant calling {#cts12758-sec-0006}
---------------

Variant frequencies were calculated by high‐throughput sequencing of the DNA collected in each sorted bin. Genomic DNA was extracted from sorted cells using DNA extraction kits (Qiagen) and amplicons were sequenced as decribed in the **Supplemental Text**. Fastq files were aligned with respective *CYP2C9* and *CYP2C19* reference sequences using BWA mem aligner version 0.7.15. Samtools mpileup version 1.5 was used with a custom python script for single nucleotide variation calling. VarScan pileup2indel version 2.3.9 was used for calling INDELS. A base quality score cutoff of 20 and a mapping quality score cutoff of 20 were applied for both single nucleotide variation and INDEL calling. Custom scripts were used to summarize the data and add allele frequencies at all positions in the reference sequence.Variant counts in each bin were tabulated and each variant's frequency in each bin was calculated. The effects of variants were obtained based on the frequency of variants in each bin.

Results {#cts12758-sec-0007}
=======

Generation of landing pad cell lines {#cts12758-sec-0008}
------------------------------------

The landing pad construct was generated and a promotor‐less cassette was constructed with ORFs for *CYP2C9* and *CYP2C19*. The ORFs were fused to GFP as an indicator of protein expression and mCherry, which was independently expressed as a transfection control. The DMS assay requires that only a single transgenetic cassette be integrated per cell, which could be guaranted by having only a single landing pad per cell (**Figure** [1](#cts12758-fig-0001){ref-type="fig"} **a**). To generate a cell line that integrated only a single copy of the landing pad, the landing pad construct was inserted into HEK 293T cells and cells were selected by BFP. Single cells positive for BFP were sorted into each well of a 96‐well plate for cloning. We observed different levels of BFP expression among different landing pad clones, probably because HEK 293T cells have been reported to have hypotriploid karyotypes.[19](#cts12758-bib-0019){ref-type="ref"} To identify a candidate clone with only a single landing pad, we selected \> 30 clones with low BFP expression levels. We then tested those clones by using bxb1 recombinase to integrate a mixture of 1:1 ratio GFP only and mCherry only promotor‐less plasmids (plasmid sequences are shown in the **Supplemental Text**) into landing pad clones, followed by flow cytometry analysis. If a candidate clone contained only a single landing pad, it would integrate either GFP or mCherry, but not both. For clone 20, quadrant Q2 for the flow cytometry showed a negligible percentage of cells with both GFP and mCherry expression (**Figure** [1](#cts12758-fig-0001){ref-type="fig"} **b**). In addition, no overlay of green and red was observed in the fluroscence image for clone 20, once again indicating that clone 20 had only a single landing pad (**Figure** [1](#cts12758-fig-0001){ref-type="fig"} **c**). As a result, clone 20 was selected for use in the following experiments. This system allowed us to monitor variant protein expression in a high‐throughput fashion.

![Generation of HEK 293T landing pad cells. (**a**) Plasmid maps of the landing pad construct and the promoter‐less cassette for CYP open reading frames that were fused to green fluorescent protein (GFP) and engineered for the simultaneous expression of IRES‐mCherry. (**b**) Flow cytometry results for landing pad HEK 293T clone 20 that had a low percentage of both GFP and mCherry, compatible with the conclusion that clone 20 contains a single landing pad. (**c**) Merged fluorescence photos showing that mCherry and GFP did not superimpose for clone 20. The landing pad clone 20 integrated either GFP or mCherry, which indicated that clone 20 contained a single landing pad. BFP, blue fluorescent protein; CMV, human cytomegalovirus promotor; IRES, internal ribosome entry site.](CTS-13-727-g001){#cts12758-fig-0001}

Effect of *CYP2C9* and *CYP2C19* variants on protein levels {#cts12758-sec-0009}
-----------------------------------------------------------

In our previous study*, CYP2C9* 218C\>T, *CYP2C9* 343A\>C, *CYP2C19*\*3 (636G\>A), and *CYP2C19* 815A\>G affected final protein quantity, resulting in varying levels of decreased protein expression.[9](#cts12758-bib-0009){ref-type="ref"} In the present study, the reporter consisted of a promoter‐less cassette containing the C‐terminus of the *CYP2C9* or *CYP2C19* ORFs fused to GFP. That construct was expressed once it was integrated into landing pad cells to ensure one variant per cell and the landing pad BFP was disrupted. Flow cytometry analysis of BFP^‐^/mCherry^+^ cells showed that known "damaging" variants expressed significantly reduced levels of GFP and lower GFP/mCherry ratios, indicating that those cells expressed less protein. Mean GFP/mCherry ratios of known damaging variants were compared with those of WT proteins. The value for *CYP2C9* 218C\>T was 28.4%; *CYP2C9* 343A\>C was 48.7%; *CYP2C19*\*3 (636G\>A) was 17.6%; and *CYP2C19* 815A\>G was 61.2% of the mean WT GFP/mCherry ratios, percentages that were roughly identical with Western blot results that we had previously reported (**Figure** [2](#cts12758-fig-0002){ref-type="fig"} **a--c**).[9](#cts12758-bib-0009){ref-type="ref"} Next, we created constructs for nonsynonymous variants with allele frequencies \> 0.00001 as reported by the Exome Aggregation Consortium and by the Mayo Clinic Right 1K study and created variant libraries for *CYP2C9* and *CYP2C19*. Pooled variant libraries for both genes were integrated into landing pad cells. Using already known damaging variants for *CYP2C9* and *CYP2C19* as well as WT constructs as references for FACS gating, the cells were sorted into different "bins" based on GFP/mCherry ratios (**Figure** [2](#cts12758-fig-0002){ref-type="fig"} **d**). Variants of *CYP2C9*/*CYP2C19* with the lowest GFP/mCherry ratios (\< 25% protein expression) were sorted into bin1 and were classified as severely damaging. WT‐like variants were sorted into bin4. The gating for four‐way sorting of *CYP2C9*/*CYP2C19* pooled variants libraries is shown in **Figure** [3](#cts12758-fig-0003){ref-type="fig"} **a,b**. Pools of cells in each bin were collected and were then used as input material for DNA sequencing. We used NGS to monitor the frequencies of variants in each bin. Variant frequencies (*F* ~v~) appearing in each bin were then used to determine protein abundance scores. Abundance scores for each *CYP2C9* and *CYP2C19* variant were calculated by use of the following equation:$$\text{Abundance\ score} = \frac{\left( {F_{\text{v,bin}1} \times 0.25} \right) + \left( {F_{\text{v,bin2}} \times 0.5} \right) + \left( {F_{\text{v,bin3}} \times 0.75} \right) + \left( {F_{\text{v,bin4}} \times 1} \right)}{\left( {F_{\text{v,bin}1} + F_{\text{v,bin}2} + F_{\text{v,bin}3} + F_{\text{v,bin}4}} \right)}$$

![Flow cytometry of cytochrome P450 family 2 subfamily C member 9 (*CYP2C9*) and cytochrome P450 family 2 subfamily C member 19 (*CYP2C19*) constructs with known variants. (**a,b**) Flow cytometry analysis of blue fluorescent protein (BFP)^‐^/mCherrry^+^ cells that integrated wild‐type or known damaging variants, *CYP2C9* 218C\>T and *CYP2C9* 343A\>C, *CYP2C19\*3* and *CYP2C19* 815A\>G. Note that for both wild‐type (WT) allozymes, most of the cells eluted toward higher green fluorescent protein (GFP)/mCherry ratios, while allozymes containing damaging variants eluted at significantly lower GFP/mCherry ratios than did the cells containing the WT. Mean GFP/mCherry ratios for those variants were consistent with Western blot results obtained during our previous study.[9](#cts12758-bib-0009){ref-type="ref"} (**c**) Cells transfected with constructs expressing known severely damaging variants (*CYP2C9* 218C\>T and *CYP2C19\*3*) eluted at low GFP/mCherry ratios, whereas other variants eluted between the two extremes (*CYP2C9* 343A\>C and *CYP2C19* 815A\>G), compatible with their being "damaging" variants. Four "bins" were established based on WT *CYP2C9* and *CYP2C19* and known damaging *CYP2C9* and *CYP2C19* variants, as shown diagramatically in (**d**).](CTS-13-727-g002){#cts12758-fig-0002}

![Fluorescence‐activated cell sorting‐sorting of pooled cytochrome P450 family 2 subfamily C member 9 (*CYP2C9*) and cytochrome P450 family 2 subfamily C member 19 (*CYP2C19*) variant libraries. Blue fluorescent protein^−^/mCherrry^+^ cells integrating *CYP2C9* and *CYP2C19* pooled variant libraries were sorted into four bins based on their green fluorescent protein (GFP)/mCherry ratios. Gates were set based on wild‐type *CYP2C9* and *CYP2C19* and known damaging *CYP2C9* and *CYP2C19* variants. Pools of sorted cells in each bin were collect and were used as input material for subsequent amplicon DNA sequencing.](CTS-13-727-g003){#cts12758-fig-0003}

For each experiment, an "abundance score" for each variant studied was obtained by multiplying the variant frequency by weighted values (0.25--1) with bin1 assigned 0.25 and bin4 with 1.0.[16](#cts12758-bib-0016){ref-type="ref"} The final abundance score for each variant was calculated by averaging mean abundance scores across replicate assays. Variants were scored in at least three experiments, as shown graphically in **Figure** [4](#cts12758-fig-0004){ref-type="fig"} and **Figure** [**S1**](#cts12758-sup-0001){ref-type="supplementary-material"}. Variants were classified as "severely damaging," "damaging," or "tolerated," with thresholds chosen on the basis of abuandance scores for known *CYP2C9/CYP2C19* variants.[9](#cts12758-bib-0009){ref-type="ref"} Using Western blot results and corresponding enzyme activities from our previous publication as a reference,[9](#cts12758-bib-0009){ref-type="ref"} *CYP2C9* variants with abundance scores below 0.578 (*CYP2C9* 1076T\>C), were classified as "severely damaging," displaying \~ 25% protein abundance as compared with WT, whereas those with abundance scores above that threshold but lower than 0.670 (*CYP2C9* 343A\>C) were classified as "damaging" displaying \~ 50% of the protein abundance of the WT allozyme. Variants with scores above this threshold were considered "tolerated." *CYP2C19* variants with abundance scores below 0.597 (*CYP2C19* 1349C\>A), were classified as "severely damaging," whereas those with abundance scores above this threshold, but lower than 0.635 (*CYP2C19* 557G\>A), were classified as "damaging." Variants with scores above this threshold were considered to be "tolerated." We found that 19 of 109 *CYP2C9* and 36 of 121 *CYP2C19* missense variants displayed less than \~ 25% of WT protein expression.

![Protein abundance scores for 109 cytochrome P450 family 2 subfamily C member 9 (*CYP2C9*) and 121 cytochrome P450 family 2 subfamily C member 19 (*CYP2C19*) variants. (**a**) Abundance score values for *CYP2C9* and *CYP2C19* variants. Variants having abundance scores lower than that for *CYP2C9* (1076T\>C) were classified as severely damaging, whereas variants having abundance scores lower than that for *CYP2C9* (343A\>C) were classified as damaging variants. The results shown are averages for four replicates. (**b**) Mean abundance scores for *CYP2C19* variants are shown in the histogram. Variants having abundance scores lower than that for *CYP2C19* (1349C\>A) were classified as severely damaging, whereas those with abundance scores lower than that for *CYP2C19* (557G\>A) were classified as damaging variants. The results shown are averages abudance scores for four replicates. SD values are listed in **Tables** [**S1**](#cts12758-sup-0002){ref-type="supplementary-material"} and [**S2**](#cts12758-sup-0003){ref-type="supplementary-material"}.](CTS-13-727-g004){#cts12758-fig-0004}

The variant calling results obtained by the use of DMS for variants from the ExAC study that had allele frequencies \> 0.00001 and variants from the Mayo RIGHT 10K study are listed in **Tables** [1](#cts12758-tbl-0001){ref-type="table"} and [2](#cts12758-tbl-0002){ref-type="table"}. The DMS results were also compared with predictions obtained using SIFT, Provean, and Polyphen2, and those results are listed in **Tables** [**\[Link\]**](#cts12758-sup-0005){ref-type="supplementary-material"}, [**\[Link\]**](#cts12758-sup-0006){ref-type="supplementary-material"} and [**\[Link\]**](#cts12758-sup-0005){ref-type="supplementary-material"}, [**\[Link\]**](#cts12758-sup-0006){ref-type="supplementary-material"} for *CYP2C9* and *CYP2C19*, respectively. For variants that resulted in dramatically reduced protein expression levels, *CYP2C9*\*11, *CYP2C9*\*21, and another 12 *CYP2C9* variants, as well as *CYP2C19*\*8, *CYP2C19*\*22, and another 26 *CYP2C19* variants, the results were in good agreement among all three of these predictive algorithms. However, five *CYP2C9* variants and seven *CYP2C19* variants displayed \< 25% of WT protein expression, whereas SIFT predicted that they were "tolerated." In summary, we found that the three commonly applied algorithms, which we tested on our 230 variants, disagreed among themselves 30.4% of the time, and they disagreed with our DMS assays, for at least one algorithm, 54.7% of the time. We also searched PharmVar, a repository for pharmacogene variation that records functionally validated variants. For *CYP2C9*\**21* and *CYP2C19*\**2B*, *\*8* and *\*22*, our results were consistent with those reported in PharmVar.[20](#cts12758-bib-0020){ref-type="ref"} However, PharmVar currently lists several allozymes for both *CYP2C9* and *CYP2C19*, which we found to be severely damaging as having only limited or moderate evidence. As a result, our results provide additional information with regard to the functional implications of these variants. Finally, 15 *CYP2C9* and 30 *CYP2C19* variants that we found to be severely damaging had not previously been reported or were reported to have uncertain function in PharmVar.[20](#cts12758-bib-0020){ref-type="ref"}

###### 

Protein abuduance scores of *CYP2C9* variants from ExAC browser and Mayo Right 10K study

  Exact cDNA    Exact amino acid   RSID          Common allele name   Allele frequency   Right 10K (variant prevalence)   DMS   PharmVar                                     
  ------------- ------------------ ------------- -------------------- ------------------ -------------------------------- ----- ---------- ------------------- ------------- --------------------
  c.752A\>G     p.His251Arg        rs2256871     CYP2C9\*9            0.006715           10079                            5     0          Damaging            0.653893822   No record
  c.449G\>A     p.Arg150His        rs7900194     CYP2C9\*8            0.005242           10074                            1     0          Damaging            0.617433538   Uncertain function
  c.1003C\>T    p.Arg335Trp        rs28371685    CYP2C9\*11           0.003784           10033                            51    0          Severely Damaging   0.549201141   possibly decreased
  c.374G\>A     p.Arg125His        rs72558189    CYP2C9\*14           0.002953           10081                            3     0          Damaging            0.627008929   No record
  c.1465C\>T    p.Pro489Ser        rs9332239     CYP2C9\*12           0.001912           10007                            77    0          Damaging            0.583353141   No record
  c.1080C\>G    p.Asp360Glu        rs28371686    CYP2C9\*5            0.001163                                                             Damaging            0.629538267   Moderate evidence
  c.801C\>T     p.Phe267hPhe       rs149158426                        0.000855                                                             Damaging            0.597268637   No record
  c.835C\>A     p.Pro279Thr        rs182132442   CYP2C9\*29           0.0004702          10080                            4     0          TOLERATED           0.672275959   possibly decreased
  c.1324G\>A    p.Gly442Ser        rs368545396                        0.0004286          10072                            12    0          Damaging            0.603761357   unknown function
  c.14T\>C      p.Val5Ala          rs138957855                        0.0003048          10077                            7     0          TOLERATED           0.688673248   No record
  c.394C\>T     p.Arg132Trp        rs199523631   CYP2C9\*45           0.0002804          10078                            6     0          Damaging            0.639522141   unknown function
  c.1264A\>G    p.Ser422Gly        rs776769484                        0.0002477          10082                            2     0          Damaging            0.627667871   No record
  c.895A\>G     p.Thr299Ala        rs72558192    CYP2C9\*16           0.0002473                                                            TOLERATED           0.673073074   No record
  c.520C\>G     p.Pro174Ala        rs199539783                        0.0001649          10079                            5     0          Damaging            0.651742423   No record
  c.269T\>C     p.Leu90Pro         rs72558187    CYP2C9 \*13          0.0001401                                                            Damaging            0.616189783   possibly decreased
  c.431G\>A     p.Arg144His        rs141489852                        0.0001401                                                            Damaging            0.651784299   No record
  c.1084C\> G   p.Leu362Val        .                                  0.000132                                                             Damaging            0.586379329   No record
  c.1088C\>T    p.Pro363Leu        rs150663116                        0.0001319          10082                            2     0          Damaging            0.581270896   possibly decreased
  c.449G\>T     p.Arg150Leu                                           0.0001319          10074                            9     0          TOLERATED           0.689018975   No record
  c.290G\>C     p.Arg97Thr         .                                  0.0001236                                                            Damaging            0.608683972   No record
  c.515G\>C     p.Cys172Ser        rs147617899                        0.0001155          10079                            5     0          TOLERATED           0.748597212   No record
  c.1034T\>C    p.Met345Thr        .                                  0.0001154                                                            Damaging            0.601859628   No record
  c.1341A\>C    p.Leu447Phe        rs59485260                         0.0001072          10079                            5     0          Damaging            0.609375      No record
  c.343A\>C     p.Ser115Arg        rs771237265                        0.000101           10082                            2     0          Damaging            0.670161008   No record
  c.1095C\>A    p.Ser365Arg        rs139532088                        0.00009894                                                           Damaging            0.578622159   Uncertain function
  c.980T\>C     p.Ile327Thr        rs57505750    CYP2C9\*31           0.0000907                                                            Damaging            0.611262013   No record
  c.89C\>T      p.Pro30Leu         rs142240658   CYP2C9\*21           0.00009067         10082                            2     0          Severely Damaging   0.483953225   Uncertain function
  c.448C\>T     p.Arg150Cys        rs17847037    CYP2C9\*48           0.00009066                                                           TOLERATED           0.710010892   No record
  c.688C\>G     p.His230Asp        .                                  0.0000837                                                            Damaging            0.65625       unknown function
  c.389C\>T     p.Thr130Met        rs200965026   CYP2C9\*44           0.00008248         10080                            4     0          Damaging            0.639755882   No record
  c.517G\>A     p.Ala173Thr        rs373758696                        0.00008247         10080                            4     0          Severely Damaging   0.548579579   No record
  c.395G\>A     p.Arg132Gln        rs200183364   CYP2C9\*33           0.00008246         10083                            1     0          TOLERATED           0.711347628   No record
  c.1362G\>C    p.Gln454His        .             CYP2C9\*19           0.00008243                                                           Damaging            0.645897332   No record
  c.680C\>T     p.Pro227Leu        .                                  0.0000756                                                            TOLERATED           0.705389146   possibly decreased
  c.1439C\>T    p.Pro480Leu        rs530950257                        0.00007417         10082                            2     0          Severely Damaging   0.479818446   possibly decreased
  c.556C\>T     p.Arg186Cys        rs150435881                        0.00006602                                                           Damaging            0.592060606   possibly decreased
  c.1166T\>C    p.Ile389Thr        .                                  0.00006597                                                           Damaging            0.631849327   No record
  c.1421A\>G    p.Asn474Ser        rs141011391                        0.00006593         10082                            2     0          Damaging            0.647619048   No record
  c.373C\>T     p.Arg125Cys        .                                  0.00005775                                                           TOLERATED           0.677726163   uncertain function
  c.1187A\>G    p.His396Arg        rs187793133                        0.00005772                                                           TOLERATED           0.700935174   No record
  c.1370A\>G    p.Asn457Ser        .             CYP2C9\*61           0.0000577                                                            Severely Damaging   0.543305795   uncertain function
  c.263T\>C     p.Ile88Thr         rs139656048                        0.00005768                                                           TOLERATED           0.676032437   No record
  c.218C\>T     p.Pro73Leu         rs762081829                        0.0000569          10083                            1     0          Severely Damaging   0.571077996   No record
  c.595G\>A     p.Glu199Lys        .                                  0.00004956                                                           Damaging            0.651252305   No record
  c.371G\>A     p.Arg124Gln        rs12414460    CYP2C9\*42           0.0000495                                                            Damaging            0.656819836   uncertain function
  c.458T\>C     p.Val153Ala        rs373993395                        0.00004945         10081                            3     0          Damaging            0.58402074    uncertain function
  c.719T\>C     p.Met240Thr        .                                  0.00004163                                                           Damaging            0.640173483   No record
  c.619A\>T     p.Ile207Phe        .                                  0.00004134                                                           TOLERATED           0.674486125   No record
  c.371G\>T     p.Arg124Leu        rs12414460                         0.00004125                                                           Severely Damaging   0.566767249   uncertain function
  c.539C\>T     p.Ser180Phe        rs200149294                        0.00004125         10083                            1     0          Severely Damaging   0.568764708   uncertain function
  c.164C\>T     p.Thr55Ile         rs771905380                        0.00004124         10082                            2     0          TOLERATED           0.701629687   No record
  c.1004G\>A    p.Arg335Gln        .             CYP2C9\*34           0.00004122                                                           TOLERATED           0.695204529   No record
  c.709G\>A     p.Val237Ile        .                                  0.00003334                                                           Damaging            0.634745896   No record
  c.624G\>C     p.Leu208Phe        .                                  0.00003308                                                           TOLERATED           0.681854013   No record
  c.538T\>C     p.Ser180Pro        .                                  0.000033                                                             Severely Damaging   0.529048923   No record
  c.541A\>G     p.Ile181Val        .                                  0.000033                                                             TOLERATED           0.689873007   No record
  c.1297C\>T    p.Arg433Trp        .                                  0.00003299                                                           Severely Damaging   0.564814815   No record
  c.386T\>A     p.Met129Lys        rs750097042                        0.00003299         10083                            1     0          Damaging            0.643411363   No record
  c.122A\>T     p.Asn41Ile         .                                  0.00003298                                                           Severely Damaging   0.458665155   No record
  c.1024A\>G    p.Arg342Gly        .                                  0.00003298                                                           Severely Damaging   0.575108971   normal function
  c.1036C\>T    p.Pro346Ser        .                                  0.00003298         10081                            3     0          Damaging            0.654218921   No record
  c.1429G\>A    p.Ala477Thr        .             CYP2C9\*30           0.00003297                                                           Severely Damaging   0.558712121   uncertain function
  c.632C\>T     p.Pro211Leu        .                                  0.00002482                                                           TOLERATED           0.692533067   No record
  c.629G\>A     p.Ser210Asn        .                                  0.00002481                                                           Damaging            0.644966918   No record
  c.600G\>T     p.Lys200Asn        rs766903671                        0.00002478         10082                            2     0          Damaging            0.663003421   No record
  c.370C\>T     p.Arg124Trp        .             CYP2C9\*43           0.00002475                                                           TOLERATED           0.737650497   No record
  c.1153A\>T    p.Thr385Ser        .                                  0.00002474                                                           Severely Damaging   0.509235183   No record
  c.863A\>G     p.Glu288Gly        .                                  0.00002474                                                           Damaging            0.601528578   No record
  c.1135T\>C    p.Tyr379His        .                                  0.00002474                                                           Damaging            0.66603031    No record
  c.433G\>T     p.Val145Phe        .                                  0.00002473                                                           Severely Damaging   0.460289634   No record
  c.1022A\>G    p.Asp341Gly        .                                  0.00002473                                                           Severely Damaging   0.470510412   No record
  c.704A\>G     p.Lys235Arg        .                                  0.00001668                                                           TOLERATED           0.68009768    uncertain function
  c.791T\>G     p.Ile264Ser        rs761895497                        0.00001656         10082                            2     0          Damaging            0.599331078   uncertain function
  c.773A\>G     p.Asn258Ser        .                                  0.00001656                                                           TOLERATED           0.684042216   No record
  c.638T\>C     p.Ile213Thr        .                                  0.00001655                                                           Damaging            0.648500178   No record
  c.637A\>C     p.Ile213Leu        .                                  0.00001655                                                           TOLERATED           0.676605037   No record
  c.618G\>T     p.Lys206Asn        .                                  0.00001654                                                           TOLERATED           0.690691147   No record
  c.356A\>C     p.Lys119Thr        .             CYP2C9\*41           0.00001651                                                           Damaging            0.601033475   decreased function
  c.1076T\>C    p.Ile359Thr        rs56165452    CYP2C9\*4            0.0000165                                                            Severely Damaging   0.578003356   possibly decreased
  c.389C\>A     p.Thr130Lys        .                                  0.0000165                                                            Damaging            0.668748634   unknown function
  c.820G\>A     p.Glu274Lys        .                                  0.0000165                                                            TOLERATED           0.687495665   No record
  c.1080C\>A    p.Asp360Glu        rs28371686                         0.00001649                                                           Damaging            0.605882567   No record
  c.137G\>A     p.Gly46Asp         .                                  0.00001649                                                           Damaging            0.611297817   No record
  c.109C\>T     p.Pro37Ser         .                                  0.00001649                                                           Damaging            0.62487462    No record
  c.1045G\>A    p.Asp349Asn        .                                  0.00001649                                                           Damaging            0.648954995   No record
  c.908G\>T     p.Ser303Ile        .                                  0.00001649                                                           Damaging            0.653594136   No record
  c.986G\>A     p.Arg329His        .                                  0.00001649                                                           Damaging            0.66037359    unknown function
  c.1136A\>G    p.Tyr379Cys        rs773704286                        0.00001649         10083                            1     0          Damaging            0.665754704   No record
  c.1214A\>T    p.Glu405Val        .                                  0.00001649                                                           TOLERATED           0.675922464   No record
  c.146A\>G     p.Asp49Gly         .             CYP2C9\*37           0.00001649                                                           TOLERATED           0.678200758   uncertain function
  c.422T\>C     p.Ile141Thr        rs148615754                        0.00001649                                                           TOLERATED           0.681659253   No record
  c.1159A\>G    p.Ile387Val        rs764211126   CYP2C9\*56           0.00001649         10083                            1     0          TOLERATED           0.688530952   No record
  c.968T\>C     p.Val323Ala        .                                  0.00001649                                                           TOLERATED           0.700837059   No record
  c.989T\>C     p.Val330Ala        .                                  0.00001649                                                           TOLERATED           0.727107621   No record
  c.257C\>A     p.Ala86Asp         .                                  0.00001648                                                           Severely Damaging   0.513086248   No record
  c.38G\>A      p.Cys13Tyr         .                                  0.00001648                                                           Damaging            0.590756013   uncertain function
  c.445G\>A     p.Ala149Thr        .             CYP2C9\*46           0.00001648                                                           Damaging            0.604943716   No record
  c.312A\>T     p.Glu104Asp        .                                  0.00001648                                                           Damaging            0.638095238   No record
  c.271G\>A     p.Gly91Arg         .                                  0.00001648                                                           Damaging            0.651222774   No record
  c.296T\>A     p.Ile99Asn         .                                  0.00001648                                                           Damaging            0.651222774   No record
  c.1415T\>C    p.Val472Ala        .                                  0.00001648                                                           Damaging            0.668443691   No record
  c.247G\>A     p.Val83Met         .                                  0.00001648                                                           Damaging            0.669561409   uncertain function
  c.460G\>A     p.Glu154Lys        .                                  0.00001648         10083                            1     0          TOLERATED           0.688904038   decreased function
  c.296T\>C     p.Ile99Thr         .                                  0.00001648                                                           TOLERATED           0.6911887     No record
  c.8C\>A       p.Ser3Tyr          .                                  0.00001648                                                           TOLERATED           0.694461693   No record
  c.791T\>C     p.Ile264Thr        rs761895497                        0.0000109          10082                            2     0          TOLERATED           0.683929331   unknown function
  c.\_del707    p.Asn236Thrfs\*5   .                                  0.000004099                                                          Severely Damaging   0.25          No record
  c.709G\>C     p.Val237Leu        .                                  Not recorded                                                         Damaging            0.623703953   No record
  c.229C\>T     p.Leu77Met         .                                  Not recorded                                                         TOLERATED           0.72516812    No record

DMS, deep mutational scanning; ExAC, Exome Aggregation Consortium; RSID, Reference SNP ID number; WT, wild‐type.
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###### 

Protein abuduance scores of *CYP2C19* variants from ExAC browser and Mayo Right 10K study

  Exact cDNA   Exact Amino acid   RSID          Common allele name   Allele Frequency   Right 10K (variant prevalence)   DMS    PharmVar                                     
  ------------ ------------------ ------------- -------------------- ------------------ -------------------------------- ------ ---------- ------------------- ------------- --------------------
  c.991G\>A    V331I              rs3758581                          0.06242            8802                             1249   33         Damaging            0.599924823   Nomal function
  c.276G\>C    E92D               rs17878459    CYP2C19\*2B          0.0236             9480                             598    6          TOLERATED           0.713318402   No record
  c.518C\>T    A173V              rs61311738                         0.005818           10080                            4      0          TOLERATED           0.643519769   No record
  c.481G\>C    A161P              rs181297724                        0.004786                                                              Severely damaging   0.475593771   No function
  c.449G\>A    R150H              rs58973490    CYP2C19\*11          0.002652           9985                             98     1          TOLERATED           0.69271491    normal function
  c.55A\>C     I19L               rs17882687    CYP2C19\*15          0.002127           10079                            5      0          Damaging            0.623042396   normal function
  c.358T\>C    W120R              rs41291556    CYP2C19\*8           0.00154            10045                            39     0          Severely damaging   0.47978285    No function
  c.1228C\>T   R410C              rs17879685    CYP2C19\*13          0.001517           10082                            2      0          TOLERATED           0.676655086   Normal function
  c.431G\>A    R144H              rs17884712    CYP2C19\*9           0.001079           10080                            4      0          Damaging            0.621114695   decreased function
  c.365A\>C    E122A              rs17885179                         0.0009637          10082                            2      0          TOLERATED           0.753787879   No record
  c.784G\>A    D262N              .                                  0.0008586                                                             Damaging            0.614038591   No record
  c.448C\>T    R150C              rs142974781                        0.0004859          10083                            1      0          Damaging            0.62953438    No record
  c.680C\>T    P227L              rs6413438     CYP2C19\*10          0.000448           10079                            5      0          Damaging            0.624712679   decreased function
  c.985C\>T    R329C              rs59734894                         0.0003872          10078                            6      0          Severely damaging   0.554502254   No record
  c.394C\>T    R132W              rs149590953                        0.0003871          10081                            3      0          Damaging            0.635242943   No record
  c.241G\>A    E81K               rs149072229                        0.0003871          10068                            16     0          TOLERATED           0.667726879   No record
  c.374G\>A    R125H              rs141774245                        0.0002965          10062                            21     0          Damaging            0.615675954   No record
  c.337G\>A    V113I              rs145119820                        0.0002718          10079                            5      0          TOLERATED           0.683885811   No record
  c.1295A\>T   K432I              rs146991374                        0.000264                                                              Damaging            0.609742945   No record
  c.217C\>T    R73C               rs145328984   CYP2C19\*30          0.0002553          10082                            1      0          Damaging            0.623329263   uncertain function
  c.1078G\>A   D360N              rs144036596                        0.0002471                                                             TOLERATED           0.693150526   None
  c.395G\>A    R132Q              rs72552267    CYP2C19\*6           0.0002389          10082                            2      0          TOLERATED           0.718026114   No function
  c.164C\>G    T55S               rs572853437                        0.000132                                                              TOLERATED           0.718673467   No record
  c.557G\>C    R186P              rs140278421   CYP2C19\*22          0.0001236          10083                            1      0          Severely damaging   0.560050139   No function
  c.1004G\>A   R335Q              rs118203757   CYP2C19\*24          0.0001236          10080                            1      0          Damaging            0.601312932   no function
  c.557G\>A    R186H                                                 0.000108                                                              Damaging            0.635198497   No record
  c.831C\>A    N277K              .                                  9.888E‐05          10080                            3      0          TOLERATED           0.681062109   No record
  c.1048G\>A   A350T              rs201509150                        9.884E‐05                                                             Severely damaging   0.536022841   No record
  c.1127T\>A   F376Y              .                                  9.884E‐05          10083                            1      0          TOLERATED           0.711485306   No record
  c.25C\>G     L9V                .                                  0.0000908                                                             TOLERATED           0.731784659   No record
  c.1007G\>T   S336I              rs143833145                        9.061E‐05                                                             TOLERATED           0.637387252   No record
  c.1036C\>T   P346S              .                                  0.0000906                                                             Severely damaging   0.580346079   No record
  c.556C\>T    R186C              rs183701923                        8.242E‐05                                                             Severely damaging   0.564313994   No record
  c.389C\>T    T130M              rs150152656                        8.237E‐05          10082                            2      0          TOLERATED           0.684802678   No record
  c.527A\>G    N176S              rs57700608                         7.417E‐05          10074                            10     0          TOLERATED           0.671875      No record
  c.1075A\>G   I359V              .                                  7.414E‐05                                                             Damaging            0.603645833   No record
  c.440A\>G    E147G              rs147453531                        7.413E‐05          10081                            3      0          TOLERATED           0.643455877   No record
  c.781C\>T    R261W              .                                  6.605E‐05                                                             Severely damaging   0.501301905   No record
  c.836A\>C    Q279P              rs61526399                         6.591E‐05                                                             Severely damaging   0.570907901   No record
  c.1001A\>T   N334I              .                                  0.0000659                                                             TOLERATED           0.648759438   No record
  c.221T\>C    M74T               .                                  6.589E‐05                                                             Severely damaging   0.58131891    No record
  c.1324C\>T   R442C              rs192154563   CYP2C19\*16          5.772E‐05                                                             Damaging            0.62128858    decreased function
  c.1021G\>C   D341H              rs770829708                        5.766E‐05          10081                            3      0          TOLERATED           0.656054948   No record
  c.85C\>T     L29F               .                                  4.946E‐05                                                             TOLERATED           0.692408379   No record
  c.837G\>T    Q279H              .                                  4.944E‐05                                                             TOLERATED           0.678912244   No record
  c.1003C\>T   R335W              rs368758960                        4.942E‐05          10083                            1      0          Severely damaging   0.497372294   No record
  c.1034T\>A   M345K              rs201132803                        4.942E‐05          10080                            1      0          Severely damaging   0.497916398   No record
  c.371G\>A    R124Q              rs200346442                        4.942E‐05                                                             Damaging            0.602183853   No record
  c.925G\>A    A309T              .                                  4.942E‐05                                                             TOLERATED           0.636880409   No record
  c.218G\>A    R73H               .                                  4.119E‐05                                                             Severely damaging   0.476206097   No record
  c.1072T\>C   Y358H              .                                  4.119E‐05                                                             TOLERATED           0.648167478   No record
  c.370C\>T    R124W              .                                  4.118E‐05                                                             Severely damaging   0.505962416   No record
  c.726T\>A    S242R              .                                  3.311E‐05                                                             TOLERATED           0.702093879   No record
  c.801C\>A    F267L              rs377674118                        3.303E‐05          10083                            1      0          Severely damaging   0.537597325   No record
  c.1171C\>G   L391V              .                                  3.298E‐05                                                             Severely damaging   0.569318436   No record
  c.1205C\>T   P402L              .                                  3.298E‐05                                                             TOLERATED           0.642305732   No record
  c.1216A\>G   M406V              rs144056033                        3.298E‐05          10082                            2      0          TOLERATED           0.699731714   No record
  c.1060G\>A   E354K              .                                  3.295E‐05                                                             Severely damaging   0.475659325   No record
  c.896C\>G    T299R              .                                  3.295E‐05                                                             Severely damaging   0.531790263   No record
  c.305T\>C    L102P              .                                  3.295E‐05                                                             Severely damaging   0.574479079   No record
  c.905C\>T    T302I              rs58259047                         3.295E‐05                                                             Damaging            0.602678118   No record
  c.1120G\>A   V374I              rs113934938   CYP2C19\*28          3.295E‐05                                                             Damaging            0.627074235   normal function
  c.961G\>T    A321S              .                                  3.295E‐05                                                             TOLERATED           0.639949178   No record
  c.928C\>T    L310F              .                                  3.295E‐05          10082                            2      0          TOLERATED           0.679301841   No record
  c.907A\>G    S303G              .                                  3.295E‐05                                                             TOLERATED           0.717662336   No record
  c.648C\>G    C216W              .                                  0.0000274                                                             TOLERATED           0.656662248   No record
  c.671A\>T    D224V              .                                  2.561E‐05                                                             Severely damaging   0.53699972    No record
  c.753C\>G    H251Q              rs148247410                        2.478E‐05                                                             Severely damaging   0.563668153   No function
  c.769A\>T    I257F              .                                  2.477E‐05                                                             TOLERATED           0.681306328   No record
  c.631C\>A    P211T              .                                  2.476E‐05                                                             TOLERATED           0.659306032   No record
  c.629C\>A    T210N              .                                  2.476E‐05                                                             TOLERATED           0.684317643   No record
  c.1316G\>T   G439V              .                                  2.474E‐05                                                             TOLERATED           0.665474123   No record
  c.1371C\>A   N457K              .                                  2.474E‐05                                                             TOLERATED           0.682756843   No record
  c.1414G\>A   V472I              .                                  2.473E‐05                                                             TOLERATED           0.670673077   No record
  c.60G\>C     W20C               .                                  2.473E‐05                                                             TOLERATED           0.672724033   No record
  c.562G\>A    D188N              rs370803989   CYP2C19\*35          2.473E‐05          10080                            4      0          TOLERATED           0.677997182   uncertain function
  c.82A\>G     K28E               .                                  2.473E‐05                                                             TOLERATED           0.680943598   No record
  c.185G\>C    G62A               .                                  2.472E‐05                                                             Severely damaging   0.508683191   No record
  c.190G\>A    V64M               rs150045105                        2.472E‐05                                                             TOLERATED           0.650769501   No record
  c.848C\>T    T283I              .                                  2.472E‐05                                                             TOLERATED           0.65615054    No record
  c.1037C\>T   P346L              .                                  2.471E‐05                                                             Severely damaging   0.502953907   No record
  c.1080C\>A   D360E              .                                  2.471E‐05                                                             Severely damaging   0.549265027   No record
  c.1078G\>C   D360H              rs144036596                        2.471E‐05          10081                            3      0          Severely damaging   0.567361111   No record
  c.373C\>T    R125C              rs200150287                        2.471E‐05          10083                            1      0          TOLERATED           0.669159602   No record
  c.850A\>G    I284V              .                                  2.471E‐05                                                             TOLERATED           0.685908298   No record
  c.430C\>T    R144C              .                                  2.471E‐05                                                             TOLERATED           0.688887841   No record
  c.721G\>A    E241K              .                                  1.657E‐05                                                             Damaging            0.619158302   No record
  c.728A\>G    D243G              .                                  1.655E‐05                                                             TOLERATED           0.696277128   No record
  c.1288G\>C   A430P              .                                  1.652E‐05                                                             Severely damaging   0.545128622   No record
  c.813G\>A    M271I              .                                  1.652E‐05                                                             TOLERATED           0.663920987   No record
  c.169C\>G    L57V               .                                  1.651E‐05                                                             Damaging            0.634196461   No record
  c.1465C\>T   P489S              .                                  0.0000165                                                             Severely damaging   0.577527563   No record
  c.1373T\>G   L458R              rs761587034                        1.649E‐05          10083                            1      0          Severely damaging   0.51802352    No record
  c.1349C\>A   T450N              rs141690375                        1.649E‐05                                                             Severely damaging   0.597025262   No record
  c.1439C\>T   P480L              rs779501712                        1.649E‐05          10083                            1      0          Damaging            0.626171339   No record
  c.1325G\>A   R442H              rs138112316                        1.649E‐05                                                             TOLERATED           0.646762738   No record
  c.65A\>G     Q22R               rs144928727                        1.649E‐05                                                             TOLERATED           0.656465743   No record
  c.1398C\>A   D466E              .                                  1.649E‐05                                                             TOLERATED           0.661470643   No record
  c.593T\>C    M198T              rs186489608                        1.649E‐05                                                             TOLERATED           0.667063402   No record
  c.1330G\>C   E444Q              .                                  1.649E‐05                                                             TOLERATED           0.694466074   No record
  c.1213G\>C   E405Q              .                                  1.649E‐05                                                             TOLERATED           0.711027827   No record
  c.518C\>A    A173D              rs61311738                         1.648E‐05          10080                            4      0          Severely damaging   0.499614976   No record
  c.1076T\>A   I359N              .                                  1.648E‐05                                                             Severely damaging   0.522206232   No record
  c.197C\>G    T66S               .                                  1.648E‐05                                                             Damaging            0.626403544   No record
  c.862G\>A    V288I              .                                  1.648E‐05                                                             TOLERATED           0.673350956   No record
  c.537C\>G    C179W              .                                  1.648E‐05                                                             TOLERATED           0.694502569   No record
  c.865A\>G    I289V              .                                  1.648E‐05                                                             TOLERATED           0.714496776   No record
  c.445G\>A    A149T              .                                  1.647E‐05                                                             Severely damaging   0.521050873   No record
  c.905C\>G    T302R              rs58259047                         1.647E‐05                                                             Severely damaging   0.521776385   No record
  c.331G\>A    G111R              .                                  1.647E‐05                                                             Severely damaging   0.541454278   No record
  c.1021G\>A   D341N              .                                  1.647E‐05                                                             Severely damaging   0.571470548   No function
  c.409G\>C    G137R              .                                  1.647E‐05                                                             Severely damaging   0.571889977   No record
  c.1013G\>T   C338F              .                                  1.647E‐05                                                             Damaging            0.609881164   No record
  c.217C\>A    R73S               rs145328984                        1.647E‐05          10082                            1      0          TOLERATED           0.651405999   No record
  c.410G\>A    G137E              .                                  1.647E‐05                                                             TOLERATED           0.653990969   No record
  c.326G\>C    G109A              .                                  1.647E‐05                                                             TOLERATED           0.658559311   No record
  c.347A\>G    N116S              .                                  1.647E‐05                                                             TOLERATED           0.666187952   No record
  c.271G\>C    G91R               rs118203756   CYP2C19\*23          1.647E‐05                                                             TOLERATED           0.668239425   uncertain function
  c.1002C\>A   N334K              rs563052490                        1.647E‐05          10081                            3      0          TOLERATED           0.687674269   No record
  c.1112C\>G   T371S              rs568155950                        1.647E‐05          10083                            1      0          TOLERATED           0.715706169   No record
  c.578A\>G    Q193R                                                 4.06E‐06                                                              TOLERATED           0.658206476   No record

ExAC, Exome Aggregation Consortium; RSID, Reference SNP ID number; WT, wild‐type.
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Validation of severely damaging variants of *CYP2C9* and *CYP2C19* {#cts12758-sec-0010}
------------------------------------------------------------------

*In silico* predictions were not always consistent with our DMS results, as described in the preceeding paragraph. That fact emphasizes the need for the validation of variant classification using DMS or other functional assays. Although the efficiency of calling damaging variants using DMS exceeded the throughput of classical mutagenesis methods, we still needed to confirm the accuracy of calling for the variants that we studied. Therefore, we validated our variant protein expression calls by the use of Western blot analyses. As shown in **Figure** [5](#cts12758-fig-0005){ref-type="fig"} **a,b**, our newly identified severely damaging variants for *CYP2C9* and *CYP2C19* displayed significantly decreased protein expression (\< 25% protein expression with the exception of *CYP2C9* 371G\>T which had \~ 50% protein expression) compared with the WT protein---shown at the far right in each of the panels. The binning patterns for variant frequencies for selected allozyme are shown in **Figures** [5](#cts12758-fig-0005){ref-type="fig"} **c,d**.

![Western blot validation of cytochrome P450 family 2 subfamily C member 9 (*CYP2C9*) and cytochrome P450 family 2 subfamily C member 19 (*CYP2C19*) allozymes identified as containing severely damaging variants. (**a,b**) The protein expression of *CYP2C9* and *CYP2C19* in blue fluorescent protein^−^/mCherry^+^ cells integrating severely damaging variants for were validated by Western blot analysis. The mCherry and β‐actin were used as loading controls. Each image includes a control lane for wild‐type (WT) *CYP2C9* or *CYP2C19*. (**c,d**) Variant frequencies for three representative "severely" damaging variants for *CYP2C9* and *CYP2C19* showing their distributions in each of the four bins.](CTS-13-727-g005){#cts12758-fig-0005}

Discussion {#cts12758-sec-0011}
==========

The functional characterization of ORF missense variants in clinically important pharmacogenes remains a major challenge for pharmacogenomics. In a recent study, we identified and functionally characterized six novel nonsynonymous ORF variants in *CYP2C9* and seven in *CYP2C19* based on Mayo Right 1K data.[9](#cts12758-bib-0009){ref-type="ref"} We found that the enzyme activities of those variants generally correlated well with protein expression levels.[9](#cts12758-bib-0009){ref-type="ref"} Missense variants in *CYP2C9*/*CYP2C19* may alter protein folding, leading to decreased protein expression as a result of accelerated proteasome‐mediated degradation, a major factor responsible for decreased enzymatic activity in pharmacogenomics.[9](#cts12758-bib-0009){ref-type="ref"}, [21](#cts12758-bib-0021){ref-type="ref"}, [22](#cts12758-bib-0022){ref-type="ref"}, [23](#cts12758-bib-0023){ref-type="ref"} The loss of function of allozymes containing nonsynonymous *CYP2C9*/*CYP2C19* ORF single nucleotide polymorphisms due to decreased protein expression made it possible to analyze their function by fluorescence reporter assays.[9](#cts12758-bib-0009){ref-type="ref"} Because of the very large number of missense variants in ORFs, it is practically difficult to link the genotypes of these variants to their functional phenotypes using "one‐at‐a‐time" expression systems. Fowler and colleagues developed DMS to analyze variants for all possible amino acid alterations in several genes. Saturation mutagenesis was also used for DMS in several previous studies.[9](#cts12758-bib-0009){ref-type="ref"}, [24](#cts12758-bib-0024){ref-type="ref"}, [25](#cts12758-bib-0025){ref-type="ref"} That approach has advantages for use in pre‐emptive pharmacogenomics and makes it possible to interpet variant function based on protein structrual mapping.[16](#cts12758-bib-0016){ref-type="ref"}, [26](#cts12758-bib-0026){ref-type="ref"} Degenerate codons were used to generate the saturation libraries but some variants of interest may be missed due to codon bias, with up to 30--50% of possible variants missing from the final data sets.[16](#cts12758-bib-0016){ref-type="ref"} *CYP2C9* and *CYP2C19* each have ORFs that are 1.6 kb in length, so it would be difficult to generate saturation mutation libraries. As a result, we chose to apply a modification of the nicking mutagenesis method developed by Whitehead *et al*.[17](#cts12758-bib-0017){ref-type="ref"} to create focused variant libraries for missense variants that had reported to occur in humans for use in our study. Specifically, we analyzed 230 nonsynonymous ORF variants for *CYP2C9* and *CYP2C19* from the ExAC study that had minor allele frequencies \> 0.00001. All of those variants had been shown to occur in humans and were not so rare as to be "private." FACS sorting was used to separate variants of differing protein expression levels, all of which were subsequently analyzed by NGS to make it possible to calculate the frequency of each of the variants studied in each of our four FACS bins (see **Figures** [2](#cts12758-fig-0002){ref-type="fig"} and [3](#cts12758-fig-0003){ref-type="fig"}).

X‐ray crystal structures have been determined for *CYP2C9* and *CYP2C19*.[27](#cts12758-bib-0027){ref-type="ref"}, [28](#cts12758-bib-0028){ref-type="ref"} Six substrate recognition sites (SRS) have been identified in CYP2C enzyme sequences: amino acids 96--117 (SRS1), 198--205 (SRS2), 233--240 (SRS3), 286--304 (SRS4), 359--369 (SRS5), and 470--477 (SRS6).[29](#cts12758-bib-0029){ref-type="ref"} Nineteen of the 75 *CYP2C9* and 9 of the 58 *CYP2C19* damaging variants listed in **Tables** [1](#cts12758-tbl-0001){ref-type="table"} and [2](#cts12758-tbl-0002){ref-type="table"}, which displayed reduced protein expression of at least 50% protein, mapped to known SRS sites, so they may also influence substrate binding. Other damaging variants listed in **Tables** [1](#cts12758-tbl-0001){ref-type="table"} and [2](#cts12758-tbl-0002){ref-type="table"} fall outside of those sites but may influence activity due to the disruption of active sites, although they have no influence on protein abundance. For example, we have reported that *CYP2C9* 709G\>C and *CYP2C19* 65A\>G displayed significantly reduced enzyme activity, but their protein levels were similar to that of that the WT.[9](#cts12758-bib-0009){ref-type="ref"} *In silico* predictions have been widely applied to predict variation in protein structure and function. Our previous work and that of others supports the importance of the application of additional, functional methods to validate results obtained by using predictive algorithms.[30](#cts12758-bib-0030){ref-type="ref"}, [31](#cts12758-bib-0031){ref-type="ref"} Therefore, we compared variant calling by use of DMS with the predictions of computational algorithms, and differences were found between our results and those of prediction algorithms, as listed in **Tables** [**S4**](#cts12758-sup-0005){ref-type="supplementary-material"} and [**S5**](#cts12758-sup-0006){ref-type="supplementary-material"}. Those differences may be due to either the accuracy of the prediction algorithms or to underlying molecular mechanisms. For example, *CYP2C9* 709G\>C and *CYP2C19* 65A\>G and *CYP2C19\*13* have WT‐like protein expression but loss of enzyme activity.[9](#cts12758-bib-0009){ref-type="ref"}, [32](#cts12758-bib-0032){ref-type="ref"} We also determined whether variants identified by DMS were truly damaging by the use of Western blot analyses, as shown in **Figure** [5](#cts12758-fig-0005){ref-type="fig"}.

A limitation of DMS based on fluorescence is that some genes have been found to not be amenable to this assay, because damaging variants for those genes had similar fluorescent intensities as did WT proteins.[16](#cts12758-bib-0016){ref-type="ref"} We found that DMS seems to be most sensitive for screening for severely damaging variants, which displayed clear fluorescence separation from WT‐like variants. However, it required careful interpretation of intermediate‐fluorescing variants. The validation of functional studies for variants characterized in this fashion will be essential if we are to incorporate these results into clinical decision making and electronic health records. To validate the most severely damaging variants that we identified by DMS, we used Western blot assays as our standard functional assay for validation, even though those studies were laborious and time‐consuming---but still necessary at this time. Protein expression is obviously an important aspect of functional genomics---but only one aspect. Additional functional validation based on enzyme activities for different CYP substrates should be performed in the future to further extend the functional characterization of the variant allozymes that we have studied. The regulation of CYP activity is a complex process involving multiple mechanisms, which include transcripton regulation by nuclear receptors, such as the pregnane X receptor, the constitutive androstane receptor, the glucocorticoid receptor and by members of the TSPYL gene family.[33](#cts12758-bib-0033){ref-type="ref"}, [34](#cts12758-bib-0034){ref-type="ref"}, [35](#cts12758-bib-0035){ref-type="ref"}, [36](#cts12758-bib-0036){ref-type="ref"} DMS, as we have used it, has the limitation of not addressing upstream DNA sequence variants, such as *CYP2C19\*17* that results in an increase in transcriptional activity.[37](#cts12758-bib-0037){ref-type="ref"}, [38](#cts12758-bib-0038){ref-type="ref"}, [39](#cts12758-bib-0039){ref-type="ref"} High‐throughput methodology for studying variants outside of ORFs will obviously be required for the interpretation of CYP variants that map outside of protein coding sequences. As a result, DMS is not a "final answer" but rather represents a significant step forward in our efforts to link genomic variation to variation in drug response phenotypes.

In summary, we have identified and validated 15 *CYP2C9* and 30 *CYP2C19* severely damaging variants that had not previously been reported in PharmVar.[20](#cts12758-bib-0020){ref-type="ref"} Those variants are potentially clinically actionable. Functional studies of those variants showed decreased protein expression, which could result in decreased drug metabolism. Our results add information that may help to improve the accuracy of current prediction algorithms and they may also provide test data sets for machine‐learning methods that might "learn" to predict the effects of ORF missense variants. The Mayo Clinic recently expanded the RIGHT 1K study to include an even larger cohort, the RIGHT 10K study that includes an additional 10,085 DNA samples with sequencing data for 77 pharmacogenes.[6](#cts12758-bib-0006){ref-type="ref"} Single nucleotide polymorphisms from both RIGHT 1K and RIGHT 10K studies were included in our analyses. This same DMS methodology can now be implemented to study other important pharmacogenes and preemptive NGS Mayo RIGHT 10K data as ever larger numbers of ORF missense variants are identified.
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